VivoSim Labs, Inc. Total Liabilities
VivoSim Labs, Inc. total liabilities. Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has total liabilities worth $6.19 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of VivoSim Labs, Inc. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of VivoSim Labs, Inc. (2011–2026)
Total liabilities of VivoSim Labs, Inc. from 2011 to 2026. This chart illustrates how VivoSim Labs, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
VivoSim Labs, Inc. Competitors by Total Liabilities
The table below lists competitors of VivoSim Labs, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lambo Group Bhd
KLSE:0018
|
Malaysia | RM17.52 Million |
|
Western Gold Exploration Ltd
V:WGLD
|
Canada | CA$9.55K |
|
Galore Resources Inc
V:GRI
|
Canada | CA$12.54 Million |
|
Subgen AI
ST:SUBGEN
|
Sweden | Skr199.12 Million |
|
Metronic Global Bhd
KLSE:0043
|
Malaysia | RM41.66 Million |
|
Kwesst Micro Systems Inc
V:KWE
|
Canada | CA$5.52 Million |
|
Visual International Holdings Ltd
JSE:VIS
|
South Africa | ZAC25.30 Million |
|
Cyabra, Inc. Common Stock
NASDAQ:CYAB
|
USA | $14.63 Million |
Liability Composition Analysis (2011–2026)
This chart breaks down VivoSim Labs, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VivoSim Labs, Inc. (VIVS) total assets.
Liquidity & Leverage Metrics
VivoSim Labs, Inc. Total Liabilities Ratios Explained
VivoSim Labs, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VivoSim Labs, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VivoSim Labs, Inc. (2011–2026)
The table below shows the annual total liabilities of VivoSim Labs, Inc. from 2011 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $8.48 Million | +104.06% |
| 2025-03-31 | $4.16 Million | +51.31% |
| 2024-03-31 | $2.75 Million | -44.86% |
| 2023-03-31 | $4.98 Million | +61.45% |
| 2022-03-31 | $3.09 Million | +328.16% |
| 2021-03-31 | $721.00K | -60.17% |
| 2020-03-31 | $1.81 Million | -58.15% |
| 2019-03-31 | $4.33 Million | -17.48% |
| 2018-03-31 | $5.24 Million | -23.13% |
| 2017-03-31 | $6.82 Million | +26.38% |
| 2016-03-31 | $5.39 Million | +12.56% |
| 2015-03-31 | $4.79 Million | +152.00% |
| 2014-03-31 | $1.90 Million | -91.37% |
| 2013-03-31 | $22.05 Million | +206147.66% |
| 2011-03-31 | $10.69K | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as… Read more